Drugs / CDK-004
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05375604 | Jun 2022 → May 2023 | colorectal cancer, gastric cancer, hepatocellular carcinoma | Codiak BioSciences | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CDK-004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05375604 ↗ |
| Route | Intravenous | “CDK-004 will be administered as a single agent intravenously (IV) at various doses.” NCT05375604 ↗ |